scrib Antibody

What is SCRIB and what role does it play in cellular biology?

SCRIB (also known as Scribble, CRIB1, LAP4, SCRB1, or VARTUL) is a large cytoplasmic scaffolding protein approximately 175-260 kDa that functions as a crucial regulator of epithelial cell polarity and tissue architecture. The protein contains multiple protein-protein interaction domains, including leucine-rich repeats (LRRs) and four PDZ domains, which facilitate its scaffolding functions . SCRIB is a fundamental component of the basolateral polarity module, working antagonistically with apical modules (Crumbs and Par) to establish and maintain cell polarity . This protein localizes primarily to tight junctions in vertebrate cells, where it ensures the correct placement of adherens junctions and influences cell adhesion and signaling pathways . SCRIB's proper functioning is essential for maintaining epithelial integrity, regulating cellular migration during development, and supporting wound healing processes in adult tissues .

How is SCRIB involved in disease processes, particularly in cancer progression?

SCRIB functions as a tumor suppressor in various contexts, with its dysregulation contributing significantly to tumorigenesis. Loss of SCRIB function disrupts apical-basal polarity and junctional integrity, leading to inappropriate cell proliferation and tissue overgrowth . Interestingly, both loss of expression and overexpression of SCRIB have been associated with cancer development, with overexpression reported in tumors of the colon, breast, lung, ovary, and prostate . The subcellular localization of SCRIB is critical to its tumor-suppressive function—proper membrane localization is required for normal function, while mislocalization to the cytoplasm or nucleus (as observed in hepatocellular carcinoma) promotes invasive properties and tumor progression . Research has demonstrated that SCRIB can act as a suppressor of tumor growth in mouse models of breast cancer, highlighting its importance in regulating cell growth and proliferation .

What protein complexes does SCRIB form, and why are they functionally significant?

SCRIB participates in multiple protein complexes that mediate its diverse cellular functions. Mass spectrometry studies have identified several key interaction partners:

• ARHGEF7-PAK-GIT protein complex: Both endogenous and ectopically expressed SCRIB co-purify with this complex, suggesting a role in cytoskeletal regulation .

• Planar Cell Polarity (PCP) pathway components: SCRIB associates with transmembrane proteins VANGL1, VANGL2, and CELSR2 (Flamingo), linking it to the PCP signaling pathway .

• NOS1AP complex: SCRIB forms a complex with NOS1AP, which also interacts with VANGL1, potentially integrating cellular polarity with nitric oxide signaling .

• Other binding partners: KCTD3 and TJP1 have been identified as novel SCRIB-associated proteins .

These protein interactions are functionally significant as they coordinate epithelial morphogenesis, control apical contractility during cell differentiation, and regulate cell migration. SCRIB's PDZ domains are particularly important in these interactions, as they bind to specific sequences at the C-terminus of target proteins, facilitating the localization of key epithelial determinants .

What criteria should researchers consider when selecting a SCRIB antibody for specific applications?

When selecting a SCRIB antibody for research, several critical factors should be considered:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IF, IHC, IP, or ELISA). For example, the SCRIB antibody from Proteintech (27083-1-AP) is validated for WB, IHC, IF, and ELISA applications .

• Species reactivity: Ensure the antibody recognizes SCRIB in your species of interest. Available antibodies show reactivity with human and mouse SCRIB samples .

• Epitope recognition: Consider which domain or region of SCRIB the antibody recognizes. For instance, the Bio-Rad polyclonal antibody targets a peptide with sequence C-PEGPGKEKELPGQ from the internal region of the protein .

• Antibody format: Determine whether a monoclonal (e.g., Scrib Antibody C-6 from Santa Cruz) or polyclonal antibody (e.g., Bio-Rad's anti-SCRIB) is more suitable for your experimental design .

• Conjugation requirements: Consider whether you need a non-conjugated antibody or one conjugated to agarose, HRP, PE, FITC, or other fluorophores for specific detection methods .

• Published validation data: Review any published literature or validation data provided by the manufacturer that demonstrates specific detection of SCRIB in your application of interest .

How can researchers validate SCRIB antibodies for their experimental systems?

Proper validation of SCRIB antibodies is essential for generating reliable research data:

• Positive and negative controls: Use cell lines known to express SCRIB (e.g., NIH/3T3 cells) as positive controls . For negative controls, employ SCRIB knockout cells created using CRISPR/Cas9 technology, as described in the literature where multiple SCRIB KO Caco-2 cell clones were generated and confirmed by Western blotting and immunofluorescence .

• Antibody specificity testing: Confirm the antibody detects a band of the expected molecular weight (approximately 175-260 kDa) in Western blots . Note that SCRIB's observed molecular weight on Western blots can vary, with reports ranging from 200-250 kDa (Bio-Rad antibody) to 260 kDa (Proteintech antibody) .

• Knockdown/knockout validation: Compare antibody signals between wildtype cells and those with SCRIB knockdown or knockout to confirm specificity. The CRISPR/Cas9 D10A double-nicking system has been used successfully to target SCRIB gene exon 1 .

• Cross-reactivity assessment: Test the antibody against related proteins to ensure it does not cross-react with other LAP family members or PDZ domain-containing proteins.

• Validation across applications: If using the antibody for multiple applications (e.g., WB and IF), validate it separately for each technique, as performance can vary between applications.

• Antibody dilution optimization: Test various dilution ranges to determine optimal conditions for each application. For example, the Proteintech antibody recommends 1:2000-1:12000 for WB and 1:50-1:500 for IHC .

What are the key differences between monoclonal and polyclonal SCRIB antibodies in research applications?

Monoclonal and polyclonal SCRIB antibodies have distinct characteristics that make them suitable for different research applications:

Monoclonal SCRIB Antibodies (e.g., C-6 from Santa Cruz):

• Recognition specificity: Recognize a single epitope on the SCRIB protein, providing high specificity for that particular region .

• Batch consistency: Offer excellent lot-to-lot consistency, making them reliable for longitudinal studies.

• Applications: The C-6 monoclonal antibody has been validated for WB, IP, IF, IHC with paraffin-embedded sections, and ELISA .

• Isotype information: Often have well-characterized isotypes (e.g., C-6 is an IgG2b kappa light chain antibody), which can be important for secondary antibody selection .

• Epitope-specific limitations: May be more susceptible to epitope masking or alteration due to protein folding or post-translational modifications.

Polyclonal SCRIB Antibodies (e.g., from Bio-Rad and Proteintech):

• Recognition breadth: Recognize multiple epitopes on the SCRIB protein, potentially providing stronger signals and greater tolerance to protein denaturation .

• Production method: Typically raised in animals (e.g., goat or rabbit) by immunization with purified antigens or peptides .

• Applications: The polyclonal antibodies have been validated for various applications, with specific recommended dilutions (e.g., 1:2000-1:12000 for WB and 1:50-1:500 for IHC with the Proteintech antibody) .

• Sensitivity advantage: Often provide higher sensitivity due to binding multiple epitopes, which can be advantageous when detecting low-abundance proteins.

• Batch variation: May show greater lot-to-lot variation compared to monoclonal antibodies.

When choosing between these antibody types, researchers should consider their specific experimental requirements, including the need for epitope specificity, signal strength, and application compatibility.

What are the optimal protocols for using SCRIB antibodies in Western blotting?

Optimizing Western blotting protocols for SCRIB detection requires attention to several key factors:

• Sample preparation:

  • Use appropriate lysis buffers that maintain protein integrity

  • Include protease inhibitors to prevent degradation

  • Denature samples completely to expose the epitope recognized by the antibody

• Gel selection and transfer:

  • Use low percentage gels (6-8%) or gradient gels to properly resolve SCRIB's high molecular weight (175-260 kDa)

  • Extend transfer times (overnight at low voltage or 2+ hours at higher voltage) to ensure complete transfer of large proteins

  • Consider wet transfer methods for more efficient transfer of high molecular weight proteins

• Antibody dilution and incubation:

  • For Proteintech's SCRIB antibody (27083-1-AP), use a dilution of 1:2000-1:12000

  • Bio-Rad's goat anti-human SCRIB antibody has been validated at 0.5-3 μg/ml for Western blotting

  • Optimize primary antibody incubation time and temperature (typically overnight at 4°C)

• Expected band detection:

  • Look for bands in the 200-260 kDa range

  • Bio-Rad's antibody detects SCRIB at approximately 200-250 kDa

  • Proteintech's antibody shows an observed molecular weight of approximately 260 kDa

• Controls and validation:

  • Include positive control samples (e.g., NIH/3T3 cell lysates)

  • Consider using SCRIB knockout or knockdown samples as negative controls

  • If available, use recombinant SCRIB protein as a positive control

• Secondary antibody selection:

  • For mouse monoclonal antibodies like Santa Cruz's C-6, use anti-mouse IgG secondaries

  • For Bio-Rad's goat antibody, compatible secondaries include rabbit anti-goat IgG (Fc):HRP (STAR122P)

  • Optimize secondary antibody dilution to minimize background

How can SCRIB antibodies be effectively used in immunofluorescence and immunohistochemistry studies?

For successful IF and IHC studies using SCRIB antibodies, researchers should follow these guidelines:

Immunofluorescence (IF):

• Sample preparation:

  • Fix cells appropriately (4% paraformaldehyde is common)

  • Permeabilize with 0.1-0.5% Triton X-100 to allow antibody access to intracellular SCRIB

  • Block with appropriate serum or BSA to reduce non-specific binding

• Antibody incubation:

  • For Bio-Rad's goat anti-SCRIB antibody, use at 10 μg/ml

  • For Santa Cruz's C-6 monoclonal antibody, follow manufacturer's recommendations

  • Consider using conjugated antibodies (FITC, PE, or Alexa Fluor conjugates) for direct detection

• Co-staining considerations:

  • SCRIB localizes to tight junctions, so co-staining with other junction markers (e.g., TJP1) can provide context

  • When studying protein complexes, co-stain for interaction partners like VANGL1 or NOS1AP

• Imaging parameters:

  • Use appropriate filters for the selected fluorophores

  • Capture z-stacks when examining junction proteins to fully visualize membrane localization

Immunohistochemistry (IHC):

• Sample preparation:

  • Both paraffin-embedded and frozen sections can be used

  • For Santa Cruz's C-6 antibody, it is validated for IHC with paraffin-embedded sections (IHCP)

  • For Proteintech's antibody, suggested antigen retrieval methods include TE buffer pH 9.0 or citrate buffer pH 6.0

• Antibody dilution:

  • For Proteintech's SCRIB antibody, use at 1:50-1:500 dilution

  • Optimize dilution for each tissue type and fixation method

• Detection systems:

  • Use appropriate secondary antibodies or detection systems based on the primary antibody host species

  • For goat primary antibodies, rabbit anti-goat secondaries are appropriate

• Positive control tissues:

  • Human ovary cancer tissue has been validated for Proteintech's antibody

  • Include tissues known to express SCRIB as positive controls

• Negative controls:

  • Include sections with primary antibody omitted

  • If possible, include tissues from SCRIB knockout models

What are the best practices for immunoprecipitation experiments using SCRIB antibodies?

Immunoprecipitation (IP) is a powerful technique for studying SCRIB protein complexes and interactions:

• Antibody selection:

  • Choose antibodies validated for IP applications, such as Santa Cruz's C-6 monoclonal antibody

  • Consider using agarose-conjugated antibodies for simplified workflows, like Santa Cruz's C-6 AC (agarose conjugate)

• Sample preparation:

  • Use gentle lysis buffers that preserve protein-protein interactions

  • Include protease and phosphatase inhibitors to maintain complex integrity

  • Clear lysates by centrifugation before antibody addition to reduce non-specific binding

• IP protocol optimization:

  • For endogenous SCRIB pull-downs, follow protocols similar to those used in published studies:

    • Use cleared protein extracts from cells (e.g., HEK293 T cells)

    • Incubate with ~10 μg of SCRIB antibody bound to protein-G-sepharose at 4°C for 2 hours

    • After washing, elute antibody complexes with sodium citrate buffer (pH 2.0)

• Analysis of immunoprecipitated complexes:

  • Western blotting can confirm successful SCRIB immunoprecipitation

  • Co-immunoprecipitation can identify interaction partners

  • Mass spectrometry provides unbiased identification of SCRIB-associated proteins

• Expected interaction partners:

  • Based on published studies, expect to detect associations with:

    • ARHGEF7, PAK, and GIT proteins

    • PCP pathway components (VANGL1, VANGL2, CELSR2)

    • NOS1AP, KCTD3, and TJP1

• Controls:

  • Include IgG control immunoprecipitations to identify non-specific binding

  • Consider reciprocal IPs with antibodies against suspected interaction partners

  • For tagged SCRIB constructs, use TAP-TAG purification approaches as described in literature

How should researchers interpret variations in SCRIB molecular weight observed in Western blots?

SCRIB's reported molecular weight varies across different studies and antibodies, which can complicate data interpretation. Researchers should consider the following factors:

• Expected molecular weight variations:

  • The calculated molecular weight based on amino acid sequence is approximately 175 kDa (for 1630 amino acids)

  • Observed molecular weights range from 200-260 kDa:

    • Bio-Rad's antibody detects SCRIB at approximately 200-250 kDa

    • Proteintech's antibody shows SCRIB at approximately 260 kDa

• Causes of molecular weight variations:

  • Post-translational modifications: Phosphorylation, glycosylation, or other modifications can increase apparent molecular weight

  • Isoform expression: Different cell types may express different SCRIB isoforms

  • Protein folding and SDS binding: Large proteins with structured domains may show aberrant migration

  • Gel percentage and running conditions: These technical factors can affect apparent molecular weight

• Validation approaches:

  • Compare with positive control samples from validated sources

  • Use SCRIB knockout or knockdown samples to confirm band specificity

  • Consider using multiple antibodies targeting different SCRIB epitopes

  • If possible, compare with recombinant SCRIB protein of known molecular weight

• Interpretation guidelines:

  • Focus on consistent band patterns rather than absolute molecular weight

  • Document the specific antibody used and the observed molecular weight

  • When comparing across experiments, maintain consistent sample preparation and gel conditions

  • Consider the specificity of the antibody and whether it might detect SCRIB fragments or degradation products

What are common challenges when using SCRIB antibodies and how can they be addressed?

Researchers may encounter several challenges when working with SCRIB antibodies:

• High molecular weight detection issues:

  • Challenge: Incomplete transfer of large proteins during Western blotting

  • Solution: Use longer transfer times, lower percentage gels, and wet transfer methods

• Specificity concerns:

  • Challenge: Cross-reactivity with related proteins containing PDZ domains

  • Solution: Validate with knockout controls and compare results using multiple antibodies targeting different epitopes

• Subcellular localization variability:

  • Challenge: SCRIB localization varies across cell types and can be mislocalized in disease states

  • Solution: Include appropriate positive control cells with known SCRIB localization patterns; use co-staining with junction markers

• Detection sensitivity:

  • Challenge: Low endogenous expression levels in some cell types

  • Solution: Optimize antibody concentration, extend exposure times, and consider signal amplification methods

• Epitope masking:

  • Challenge: Protein-protein interactions may block antibody binding sites

  • Solution: Test multiple antibodies targeting different SCRIB regions; optimize fixation and permeabilization conditions

• Background signal:

  • Challenge: High background, particularly in immunostaining

  • Solution: Optimize blocking conditions, antibody dilutions, and washing steps; consider using more specific detection systems

How can researchers distinguish between specific and non-specific binding of SCRIB antibodies?

Distinguishing specific from non-specific binding is critical for accurate data interpretation:

• Essential controls:

  • Use SCRIB knockout or knockdown samples generated by CRISPR/Cas9 or RNAi technology

  • Include isotype controls for monoclonal antibodies

  • Perform peptide competition assays with the immunizing peptide when available

• Multiple antibody validation:

  • Compare results using different antibodies targeting distinct SCRIB epitopes

  • Consistent results across antibodies suggest specific detection

• Application-specific validation:

  • For Western blotting: Verify that the detected band matches the expected molecular weight (200-260 kDa) and disappears in knockout samples

  • For immunostaining: Confirm that the localization pattern matches known SCRIB distribution (e.g., tight junctions in epithelial cells)

  • For immunoprecipitation: Verify co-IP of known SCRIB interaction partners

• Signal evaluation:

  • Specific signals should show reproducible patterns across experimental replicates

  • Non-specific binding often appears as smeared or multiple unexpected bands

  • In immunostaining, specific signals should show subcellular distribution consistent with SCRIB biology

• Technical optimization:

  • Adjust antibody dilutions to minimize background while maintaining specific signal

  • Optimize blocking conditions to reduce non-specific binding

  • Increase washing stringency to remove weakly bound antibodies

How can SCRIB antibodies be used to investigate epithelial morphogenesis and polarity?

SCRIB antibodies are valuable tools for studying epithelial morphogenesis and polarity:

• Experimental systems:

  • Epithelial cell lines (e.g., Caco-2) grown in 2D culture or 3D systems

  • Intestinal organoid cultures (IOCs) made of flexible silicone polymer (PDMS)

  • Tissue sections from developmental stages or adult organs

• Methodological approaches:

  • Immunofluorescence to visualize SCRIB localization at cell-cell junctions

  • Co-immunostaining with other polarity markers (apical, lateral, basal) to assess polarity establishment

  • Live-cell imaging with fluorescently tagged SCRIB to monitor dynamic localization during morphogenesis

• Key research questions:

  • How does SCRIB contribute to apical contractility during epithelial differentiation?

  • What is the temporal relationship between SCRIB localization and junction formation?

  • How do SCRIB protein complexes regulate epithelial architecture?

• Experimental designs:

  • Compare wildtype cells with SCRIB knockout or knockdown models

  • Examine SCRIB localization during epithelial differentiation timecourses

  • Assess effects of disrupting SCRIB's protein-protein interactions on epithelial architecture

• Data interpretation:

  • In normal epithelia, SCRIB localizes to tight junctions and is essential for maintaining epithelial integrity

  • Loss of SCRIB function disrupts apical-basal polarity and junctional integrity

  • SCRIB controls epithelial apical contractility during cell differentiation

What techniques are used to study SCRIB protein complexes and interaction partners?

Multiple complementary techniques can be used to study SCRIB protein complexes:

• Co-immunoprecipitation and mass spectrometry:

  • Immunoprecipitate endogenous or tagged SCRIB from cell lysates

  • Analyze associated proteins by tandem mass spectrometry

  • This approach has identified interactions with ARHGEF7, PAK, GIT proteins, VANGL1/2, CELSR2, NOS1AP, KCTD3, and TJP1

• Reciprocal co-immunoprecipitation:

  • Immunoprecipitate suspected interaction partners (e.g., NOS1AP)

  • Probe for SCRIB in the precipitated complexes by Western blotting

  • This approach confirmed the NOS1AP-SCRIB-VANGL1 complex

• Tandem affinity purification:

  • Express TAP-tagged SCRIB in cells (as used in HEK293 T cells)

  • Purify complexes through sequential affinity steps

  • This method provides higher purity complexes for mass spectrometry analysis

• Proximity labeling techniques:

  • Express SCRIB fused to BioID or APEX2

  • Identify proteins in proximity to SCRIB through biotinylation

  • This approach can capture transient or weak interactions

• Protein domain mapping:

  • Express truncated versions of SCRIB lacking specific domains

  • Identify which domains are required for specific protein interactions

  • Focus on PDZ domains, which are known to bind specific sequences at the C-terminus of target proteins

How is SCRIB involved in cancer research and what methodological approaches are used?

SCRIB plays complex roles in cancer, functioning as both a tumor suppressor and potential oncogene depending on context:

• Expression analysis approaches:

  • Immunohistochemistry of tumor tissue microarrays to assess SCRIB expression levels

  • Western blotting of tumor samples compared to matched normal tissues

  • These approaches have revealed overexpression of SCRIB in tumors of the colon, breast, lung, ovary, and prostate

• Localization studies:

  • Immunofluorescence to determine SCRIB subcellular localization in tumor samples

  • This has revealed mislocalization to the cytoplasm or nucleus in some cancers, including hepatocellular carcinoma

  • Proper membrane localization is required for SCRIB's tumor-suppressive function

• Functional studies:

  • SCRIB knockdown or knockout in cancer cell lines to assess effects on proliferation, migration, and invasion

  • Overexpression of SCRIB in appropriate model systems

  • Mouse models have demonstrated SCRIB's role as a suppressor of tumor growth in breast cancer

• Mechanistic studies:

  • Analysis of SCRIB's effects on signaling pathways relevant to cancer

  • Investigation of how SCRIB regulates junctional integrity and cell polarity

  • Studies of how loss of SCRIB function promotes inappropriate proliferation and tissue overgrowth

• Therapeutic targeting approaches:

  • Identification of strategies to restore proper SCRIB localization or function

  • Development of small molecules that could modulate SCRIB-dependent pathways

  • Creation of peptide inhibitors that could disrupt oncogenic SCRIB interactions

These methodological approaches collectively provide insights into SCRIB's roles in cancer initiation, progression, and potential therapeutic targeting.